LIFELINE PHARMA AS

0160 OSLO

Finances

Share Ownership

Return on Equity

−304,21 %

Current Ratio

1,38

Debt-to-Equity Ratio

−16,03

Key figures (NOK)	2022	2021	2020	2019
Revenue	18 096 000	30 690 000	36 078 000	35 594 000
Net Income	794 000	−2 468 000	548 000	−2 985 000
Total Assets	12 791 000	14 645 000	13 279 000	12 296 000
Total Equity	−261 000	−1 371 000	−1 896 000	−2 444 000

Income (NOK)	2022	2021	2020	2019
Revenue	18 096 000	30 690 000	36 078 000	35 594 000
Expenditure	17 043 000	32 984 000	34 924 000	38 350 000
Operating Profit	1 052 000	−2 294 000	1 155 000	−2 757 000
Financial Income	229 000	186 000	108 000	3 000
Financial Costs	488 000	361 000	715 000	231 000
Financial Balance	−259 000	−175 000	−607 000	−228 000
Earnings Before Tax	794 000	−2 468 000	548 000	−2 985 000
Tax	0	0	0	0
Net Income	794 000	−2 468 000	548 000	−2 985 000

Balance (NOK)	2022	2021	2020	2019
Total Fixed Assets	559 000	513 000	506 000	54 000
Total Current Assets	12 232 000	14 133 000	12 773 000	12 242 000
Total Assets	12 791 000	14 645 000	13 279 000	12 296 000
Total Retained Equity	−361 000	−1 471 000	−1 996 000	−2 544 000
Total Equity	−261 000	−1 371 000	−1 896 000	−2 444 000
Total Long-Term Debt	4 185 000	1 772 000	3 707 000	3 707 000
Total Current Debt	8 867 000	14 243 000	11 468 000	11 033 000
Total Equity and Debt	12 791 000	14 645 000	13 279 000	12 296 000

Cash flow (NOK)	2022	2021	2020	2019
Sales Income	18 096 000	30 690 000	36 078 000	35 594 000
Other Income	0	0	0	0
Revenue	18 096 000	30 690 000	36 078 000	35 594 000
Cost of Goods Sold	9 153 000	21 035 000	22 882 000	26 573 000
Salary Costs	2 112 000	2 611 000	2 444 000	2 412 000
Depreciation	7 000	7 000	7 000	41 000
Impairment	0	0	0	0
Expenditure	17 043 000	32 984 000	34 924 000	38 350 000
Operating Profit	1 052 000	−2 294 000	1 155 000	−2 757 000
Financial Income	229 000	186 000	108 000	3 000
Financial Costs	488 000	361 000	715 000	231 000
Financial Balance	−259 000	−175 000	−607 000	−228 000
Dividends	0	0	0	0
Net Income	794 000	−2 468 000	548 000	−2 985 000

Balance details (NOK)	2022	2021	2020	2019
Goodwill	0	0	0	0
Total Intangible Assets	0	0	0	0
Real Eastate	0	0	0	0
Machinery and Plant Facilities	0	0	0	0
Fixtures	9 000	16 000	23 000	29 000
Total Tangible Assets	9 000	16 000	23 000	29 000
Total Fiancial Fixed Assets	549 000	497 000	484 000	25 000
Total Fixed Assets	559 000	513 000	506 000	54 000
Stock	6 321 000	5 703 000	4 136 000	3 177 000
Total Investments	0	0	0	0
Cash, Bank	202 000	893 000	412 000	1 032 000
Total Current Assets	12 232 000	14 133 000	12 773 000	12 242 000
Total Assets	12 791 000	14 645 000	13 279 000	12 296 000
Total Equity	−261 000	−1 371 000	−1 896 000	−2 444 000
Short-Term Group Debt	0	0	0	0
Total Long-Term Debt	4 185 000	1 772 000	3 707 000	3 707 000
Creditors	5 157 000	12 372 000	8 760 000	7 878 000
Unpaid Taxes	83 000	294 000	201 000	248 000
Dividends	0	0	0	0
Other Current Debt	3 627 000	1 577 000	2 507 000	2 907 000
Total Current Debt	8 867 000	14 243 000	11 468 000	11 033 000
Total Equity and Debt	12 791 000	14 645 000	13 279 000	12 296 000

Financial indicators	2022	2021	2020	2019
Return on Equity	−304,21 %	180,01 %	−28,9 %	122,14 %
Debt-to-Equity Ratio	−16,03	−1,29	−1,96	−1,52
Operating Profit Margin	5,81 %	−7,47 %	3,2 %	−7,75 %
Current Ratio	1,38	0,99	1,11	1,11
Quick Ratio	4,8	1,65	1,74	1,56
Equity Ratio	−0,02	−0,09	−0,14	−0,2
Gross Profit Margin	49,42 %	31,46 %	36,58 %	25,34 %